AtheroNova (AHRO) Adds Experienced Clinical Affairs Officer to Management Team
Posted on January 08, 2013 at 12:11 PM EST
AtheroNova Inc. (OTCQB: AHRO), developer of an innovative potential treatment for atherosclerotic plaque, could revolutionize the market for cardiovascular health. Unlike Pfizer Inc.’s (NYSE: PFE) Lipitor® or AstraZeneca plc’s (NYSE: AZN) Crestor, the Company’s AHRO-001 has the potential to actually regress or remove the underlying cause of many cardiovascular diseases. Recently, the company has been